Palvella Therapeutics, Inc. (PVLA)
Palvella Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Wayne, PA, US. The stock last traded at $154.70, up 0.26% on the session, giving a market capitalisation of $2.22B. On trailing twelve-month figures it carries a trailing P/E of -32.03, a net margin of 0.0%. Its beta of -0.17 implies it has historically moved less than the broad market.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Palvella Therapeutics, Inc. is most often compared with the following Healthcare names: